MedWatch

2curex enters collaboration with US oncology firm

Danish 2curex has joined forced with US-based Gibson Oncology to develop a new anti-cancer drug. 2cureX will use its own technology to select the right patients for the project that is said to have great commercial potential.

Foto: 2curex

Danish company 2curex enters a lucrative collaboration with US-based oncology firm, Gibson Oncology.

Together, the parties will take Gibson's candidate LMP400 through phase II trials. The drug already showed promising phase I data.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier